The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis

Exclusion Criteria

• •1. Conditions associated with increased risk of bleeding
• •2. Any thrombolytic therapy within last 7 days
• •3. Cerebellar venous thrombosis with 4th ventricle compression and hydrocephalus, which requires surgery
• •4. Contraindication for anti-coagulant or batroxobin treatment 1)documented generalized bleeding disorder 2)concurrent thrombocytopenia (\<100 x 10E9/L) 3)Fibrinogen below 100mg /dl 4)documented severe hepatic or renal dysfunction, that interferes with normal coagulation 5)uncontrolled severe hypertension (diastolic \> 120 mm Hg) 6)known recent (\< 3 months) gastrointestinal tract hemorrhage (not including hemorrhage from rectal hemorrhoids)
• •5. Any known associated condition (such as terminal cancer) with a poor short term (1 year) prognosis independent of CVST
• •6. Clinical and radiological signs of impending transtentorial herniation due to large space-occupying lesions (e.g. large cerebral venous infarcts or hemorrhages)
• •7. Recent (\< 2 weeks) major surgical procedure (does not include lumbar puncture) or severe cranial trauma
• •8. Previously legally incompetent prior to CVST
• •9. Severe renal impairment
• •10. Active liver disease
• •11. Pregnancy, nursing or planning to become pregnant while in the trial
• •13. No informed consent.